Market Research Logo

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Summary

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.In 2015, the NSCLC market in the 5EU was an estimated $1.53B. This growth is fueled by the increasing use of immunotherapies across histologies and lines of therapy in NSCLC. Particularly, the use of PD-1 checkpoint inhibitors in first-line therapy of NSCLC is expected to take away significant sales from conventional chemotherapies that are typically used in the first line. Merck & Co.’s Keytruda is the current front-runner in the first-line setting, as it’s already approved as a monotherapy for ≥50% PD-L1+ patients, and is showing benefit in combination with chemotherapy regardless of PD-L1 expression.

Scope

  • Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2015-2025.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU NSCLC market.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2015-2025 in 5EU.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
4.2 France
4.3 Germany
4.4 Italy
4.5 Spain
4.6 UK
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - Major Brands, Epidermal Growth Factor Receptor-Targeting
5.2.1 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
5.2.2 Tarceva (erlotinib hydrochloride)
5.2.3 Iressa (gefitinib)
5.2.4 Gilotrif (afatinib)
5.2.5 Tagrisso (osimertinib)
5.2.6 Portrazza (necitumumab)
5.2.7 Conmana (icotinib)
5.3 Product Profiles - Major Brands, Anaplastic Lymphoma Kinase-Targeting
5.3.1 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors
5.3.2 Xalkori (crizotinib)
5.3.3 Zykadia (ceritinib)
5.3.4 Alecensa (alectinib)
5.4 Product Profiles - Major Brands, Monoclonal Antibodies
5.4.1 Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors
5.4.2 Opdivo (nivolumab)
5.4.3 Keytruda (pembrolizumab)
5.4.4 Tecentriq (atezolizumab)
5.5 Product Profiles - Major Brands, Other
5.5.1 Avastin (bevacizumab)
5.5.2 Cyramza (ramucirumab)
5.5.3 Vargatef/Ofev (nintedanib)
5.6 Chemotherapies
6 Unmet Needs Assessment and Opportunity Analysis
6.1 Overview
6.2 First-Line Treatments That Extend Overall Survival in Advanced-Stage Nonsquamous NSCLC Without Actionable Mutations
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Therapies Targeting Novel Biomarkers
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Treatment Options for Squamous Patients in the First-Line and Third-Line Setting
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Alternative Testing Options for Patients with Insufficient Biopsy Material
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Treatments for Patients with Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Immune Checkpoint Inhibitors
7.2.2 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
7.2.3 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors
7.2.4 Therapeutic Cancer Vaccines
7.2.5 Anti-angiogenic Therapies
7.2.6 Avastin (bevacizumab) Biosimilars
7.2.7 KRAS Inhibitors
7.2.8 Tafinlar (dabrafenib) + Mekinist (trametinib)
7.2.9 Veliparib (ABT-888)
7.2.10 Seribantumab (MM-121)
7.2.11 IMMU-132 (sacituzumab govitecan)
7.2.12 Plinabulin (NPI-2358)
7.3 Promising Drugs in Early-Stage Development
7.3.1 Immune Checkpoint Inhibitors
7.3.2 Anaplastic Lymphoma Kinase Inhibitors
7.3.3 Neurotropic Tropomyosin-Related Kinase Inhibitors
7.3.4 MET inhibitors
7.3.5 Rearranged During Transfection Inhibitors
7.3.6 Human Epidermal Growth Factor 2 Inhibitors
7.3.7 PI3K Pathway Inhibitors
8 Market Outlook
8.1 5EU
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed NSCLC Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Primary Research - KOLs
9.5.1 KOLs
9.6 About the Authors
9.6.1 Analyst
9.6.2 Therapy Area Director
9.6.3 Epidemiologist
9.6.4 Global Head of Healthcare
9.7 About GlobalData
9.8 Disclaimer
1.1 List of Tables
Table 1: Definitions Used in the AJCC Lung Cancer Staging System
Table 2: AJCC Staging of NSCLC
Table 3: Symptoms of NSCLC
Table 4: Prognostic Factors for NSCLC
Table 5: Prognosis for NSCLC Based on Initial Staging
Table 6: Prevalence of Brain and Bone Metastases in NSCLC
Table 7: Biomarker Testing Rates in Nonsquamous NSCLC
Table 8: Biomarker Testing Rates in Squamous NSCLC
Table 9: Treatment Guidelines for NSCLC
Table 10: Most Prescribed Drugs for NSCLC by Class in the 8MM, 2015-2025
Table 11: Country Profile - France
Table 12: Country Profile - Germany
Table 13: Country Profile - Italy
Table 14: Country Profile - Spain
Table 15: Country Profile - UK
Table 16: Leading Treatments for NSCLC, 2016
Table 17: Marketed EGFR TKIs in NSCLC
Table 18: Product Profile - Tarceva
Table 19: Efficacy of Tarceva in First-Line Therapy, EGFR-mutant NSCLC
Table 20: Efficacy of Tarceva in Maintenance Therapy in NSCLC
Table 21: Efficacy of Tarceva in Second- and Third-Line Therapy in NSCLC
Table 22: Safety of Tarceva
Table 23: Tarceva SWOT Analysis, 2016
Table 24: Product Profile - Iressa
Table 25: Efficacy of Iressa in First-Line, EGFR-Mutant NSCLC (Study 1)
Table 26: Efficacy of Iressa in First-Line, EGFR-Mutant ADC NSCLC (Study 2)
Table 27: Safety of Iressa
Table 28: Iressa SWOT Analysis, 2016
Table 29: Product Profile - Gilotrif
Table 30: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 31: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 32: Efficacy of Gilotrif in Second-Line, EGFR-Wildtype, EGFR TKI-Naïve, Squamous NSCLC
Table 33: Efficacy of Gilotrif in Fourth-Line, EGFR-Mutant NSCLC
Table 34: Safety of Gilotrif
Table 35: Gilotrif SWOT Analysis, 2016
Table 36: Product Profile - Tagrisso
Table 37: Efficacy of Tagrisso in Second-Line, EGFR-Mutant NSCLC
Table 38: Safety of Tagrisso
Table 39: Tagrisso SWOT Analysis, 2016
Table 40: Product Profile - Portrazza
Table 41: Efficacy of Portrazza in First-Line, Squamous NSCLC
Table 42: Safety of Portrazza
Table 43: Portrazza SWOT Analysis, 2016
Table 44: Efficacy of Conmana in 2L Advanced NSCLC
Table 45: Efficacy of Conmana in 1L EGFR-mutant NSCLC
Table 46: Safety of Conmana
Table 47: Conmana SWOT Analysis, 2016
Table 48: Marketed ALK TKIs in NSCLC
Table 49: Product Profile - Xalkori
Table 50: Efficacy of Xalkori in Treatment-Naïve ALK+ Metastatic NSCLC
Table 51: Efficacy of Xalkori in Previously Treated ALK+ Metastatic NSCLC
Table 52: Safety of Xalkori in Treatment-Naïve, ALK+ Metastatic NSCLC
Table 53: Safety of Xalkori in Previously Treated, Metastatic NSCLC
Table 54: Xalkori SWOT Analysis, 2016
Table 55: Product Profile - Zykadia
Table 56: Efficacy of Zykadia
Table 57: Safety of Zykadia
Table 58: Zykadia SWOT Analysis, 2016
Table 59: Product Profile - Alecensa
Table 60: Efficacy of Alecensa
Table 61: Efficacy of Alecensa in NSCLC patients with CNS lesions
Table 62: Safety of Alecensa
Table 63: Alecensa SWOT Analysis, 2016
Table 64: Marketed PD-1/PD-L1 ICIs in NSCLC
Table 65: Product Profile - Opdivo
Table 66: Efficacy of Opdivo in Metastatic Squamous NSCLC
Table 67: Efficacy of Opdivo in Metastatic Nonsquamous NSCLC
Table 68: Safety of Opdivo
Table 69: Opdivo SWOT Analysis, 2016
Table 70: Product Profile - Keytruda
Table 71: Efficacy of Keytruda
Table 72: Safety of Keytruda
Table 73: Keytruda SWOT Analysis, 2016
Table 74: Product Profile - Tecentriq (atezolizumab)
Table 75: Patient Demographics in the Phase II POPLAR Trial (NCT01903993)
Table 76: Efficacy of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 77: Efficacy of Tecentriq in the Phase III OAK Trial (NCT02008227)
Table 78: Patient Demographics in the Phase II FIR Trial (NCT01846416)
Table 79: Efficacy of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 80: Efficacy of Tecentriq in the Phase II BIRCH Trial (NCT02031458)
Table 81: Safety of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 82: Safety of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 83: Tecentriq SWOT Analysis, 2016
Table 84: Product Profile - Avastin
Table 85: Efficacy of Avastin in Nonsquamous NSCLC
Table 86: Safety of Avastin
Table 87: Avastin SWOT Analysis, 2016
Table 88: Product Profile - Cyramza
Table 89: Efficacy of Cyramza
Table 90: Safety of Cyramza
Table 91: Cyramza SWOT Analysis, 2016
Table 92: Product Profile - Vargatef
Table 93: Efficacy of Vargatef in ADC NSCLC
Table 94: Safety of Vargatef in ADC NSCLC
Table 95: Vargatef SWOT Analysis, 2016
Table 96: Summary of Chemotherapies, 2015
Table 97: Unmet Need and Opportunity in NSCLC
Table 98: Product Profile - Yervoy (ipilimumab)
Table 99: Demographics in the Phase II NCT00527735 Trial
Table 100: Efficacy of Yervoy + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 101: Demographics in the Phase I CheckMate 012 Trial (NCT01454102)
Table 102: Efficacy of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 103: Safety of Yervoy (ipilimumab) + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 104: Safety of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 105: Yervoy SWOT Analysis, 2016
Table 106: Product Profile - Avelumab (MSB-0010718C)
Table 107: Patient Demographics in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 108: Efficacy of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 109: Efficacy of Avelumab in PD-L1-Positive and -Negative NSCLC
Table 110: Demographics in the Treatment-Naïve NSCLC Cohort in the Phase I Trial (NCT01772004)
Table 111: Efficacy of Avelumab in Treatment-Naïve NSCLC
Table 112: Unconfirmed ORR According to PD-L1 Expression in Treatment-Naïve NSCLC
Table 113: Safety of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 114: Safety of Avelumab in Treatment-Naïve NSCLC (NCT01772004)
Table 115: Avelumab SWOT Analysis, 2016
Table 116: Product Profile - Durvalumab (MEDI4736)
Table 117: Patient Demographics and Disease Characteristics in the Phase I/II NCT01693562 Trial
Table 118: Efficacy of Durvalumab in the Phase I/II NCT01693562 Trial
Table 119: Baseline Characteristics of Patients With Treatment-Naïve NSCLC in the Phase I/II
Table 120: Efficacy of Durvalumab in Treatment-Naïve NSCLC
Table 121: Patient Demographics and Disease Characteristics in the Phase Ib NCT02000947 Trial
Table 122: Efficacy of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 123: Safety of Durvalumab in the Phase I/II Trial (NCT01693562)
Table 124: Safety of Durvalumab in Treatment-Naïve NSCLC
Table 125: Safety of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 126: Durvalumab SWOT Analysis, 2016
Table 127: Product Profile - Naquotinib Mesylate (ASP8273)
Table 128: Patient Demographics in the Phase I/II NCT02192697 and Phase I NCT02113813 Trials
Table 129: Efficacy of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 130: Safety of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 131: Naquotinib SWOT Analysis, 2016
Table 132: Product Profile - Olmutinib (BI 1482694; HM61713)
Table 133: Demographics in the Phase I/II NCT01588145 Trial
Table 134: Efficacy of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 135: Safety Profile of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 136: Olmutinib SWOT Analysis, 2016
Table 137: Product Profile - Dacomitinib
Table 138: Demographics in the Phase II NCT00818441 Trial
Table 139: Efficacy of Dacomitinib in the Phase II NCT00818441 Trial
Table 140: Safety of Dacomitinib in Phase II NCT00818441 Trial
Table 141: Dacomitinib SWOT Analysis, 2016
Table 142: Product Profile - Ensartinib
Table 143: Baseline Patient Characteristics in the Phase I/II eXalt2 Trial (NCT0162534)
Table 144: Efficacy of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 145: Baseline Patient Characteristics in the Expansion Cohort of the Phase I/II eXalt2 Trial
Table 146: Efficacy of Ensartinib in the Expansion Phase of the eXalt2 Trial (NCT0162534)
Table 147: Safety of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 148: Ensartinib SWOT Analysis, 2016
Table 149: Product Profile - Brigatinib
Table 150: Baseline Patient Characteristics in the Phase II ALTA Trial (NCT02094573)
Table 151: Efficacy of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 152: Efficacy of Brigatinib in ALK+ NSCLC with Intracranial CNS Metastases
Table 153: Safety of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 154: Brigatinib SWOT Analysis, 2016
Table 155: Product Profile - CimaVax-EGF
Table 156: Demographics in the Phase III trial of the CimaVax-EGF in Cuba
Table 157: Efficacy of the CimaVax-EGF in the Phase III trial in Cuba
Table 158: Safety of the CimaVax-EGF in the Phase III Trial in Cuba
Table 159: CimaVax-EGF SWOT Analysis, 2016
Table 160: Product Profile - Tedopi
Table 161: Demographics in the Phase II Trial of Tedopi in Advanced NSCLC
Table 162: Efficacy of Tedopi in Advanced NSCLC
Table 163: Tedopi SWOT Analysis, 2016
Table 164: Product Profile - Anlotinib
Table 165: Efficacy of Anlotinib in Pretreated NSCLC in the Phase II ALTER0302 Trial
Table 166: Anlotinib SWOT Analysis, 2016
Table 167: Product Profile - Aitan
Table 168: Efficacy of Aitan in Pretreated Nonsquamous NSCLC
Table 169: Aitan SWOT Analysis, 2016
Table 170: Product Profile - Fruquintinib
Table 171: Baseline Demographics in the Phase I Trial (HMP, NCT01645215) of Fruquintinib
Table 172: Efficacy of Fruquintinib in Advanced Solid Tumors
Table 173: Safety of Fruquintinib in Advanced Solid Tumors
Table 174: Fruquintinib SWOT Analysis, 2016
Table 175: Efficacy and Safety of ABP 215 in NSCLC in the Phase III Trial (NCT01966003)
Table 176: Product Profile - Abemaciclib
Table 177: Efficacy of Abemaciclib Monotherapy in Previously Treated NSCLC (NCT01394016)
Table 178: Efficacy of Abemaciclib in Combination with Other Therapies (NCT02079636)
Table 179: Safety of Abemaciclib in Combination with Multiple Single Agents
Table 180: Abemaciclib SWOT Analysis, 2016
Table 181: Product Profile - Tafinlar + Mekinist
Table 182: Demographics in Cohort B of the Pivotal Phase II BRF113928 Trial (GSK, NCT01336634)
Table 183: Efficacy of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 184: Safety of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 185: Tafinlar + Mekinist SWOT Analysis, 2016
Table 186: Product Profile - Veliparib
Table 187: Demographics in the Phase II NCT01560104 Trial
Table 188: Efficacy of VCP in Advanced NSCLC (NCT01560104)
Table 189: Efficacy of VCP by Smoking Status (NCT01560104)
Table 190: Safety of VCP in Advanced NSCLC (NCT01560104)
Table 191: Veliparib SWOT Analysis, 2016
Table 192: Product Profile - Seribantumab (MM-121)
Table 193: Demographics in Group A of the Phase I/II Trial (NCT00994123) of MM-121 + Tarceva in
Table 194: Efficacy of MM-121 + Tarceva in EGFR Wild-Type NSCLC
Table 195: Safety of MM-121 + Tarceva in EGFR Wild-Type NSCLC
Table 196: MM-121 SWOT Analysis, 2016
Table 197: Product Profile - Sacituzumab govitecan (IMMU-132)
Table 198: Demographics in the Phase II Portion of the Phase I/II Trial (NCT01631552)
Table 199: Efficacy of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)
Table 200: Efficacy of IMMU-132 in Patients Who Progressed on Prior Checkpoint Inhibitor
Table 201: Safety of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)
Table 202: IMMU-132 SWOT Analysis, 2016
Table 203: Product Profile - Plinabulin
Table 204: Efficacy of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)
Table 205: Safety of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)
Table 206: Plinabulin SWOT Analysis, 2016
Table 207: Early-Stage Clinical Development in NSCLC
Table 208: MET Status in the Phase II (NCT01610336) Trial
Table 209: Efficacy of Capmatinib + Iressa in MET+ NSCLC
Table 210: Demographics in the Phase II LURET Study
Table 211: Efficacy of Caprelsa in RET+ NSCLC
Table 212: Demographics in the Stage I of the Phase II NCT01639508 Trial
Table 213: Efficacy of Cometriq in RET+ NSCLC
Table 214: Key Events Impacting Sales for NSCLC in the 5EU, 2016
Table 215: NSCLC -Drivers and Barriers in the 5EU, 2015‒2025
Table 216: Key Launch Dates - Part I
Table 217: Key Launch Dates - Part II
Table 218: Key Patent Expiries
Table 219 Average Body Weight and Surface Area Across the 8MM
Table 216: Average Cost of Therapy of Alimta in the 8MM
Table 217: Average Cost of Therapy of Alecensa in the 8MM
Table 218: Average Cost of Therapy of Avastin
Table 219: Average Cost of Therapy of Cyramza
Table 220: Average Cost of Therapy of Gilotrif
Table 221: Average Cost of Therapy of Iressa
Table 222: Average Cost of Therapy of Portrazza
Table 223: Average Cost of Therapy of Tagrisso
Table 224: Average Cost of Therapy of Tarceva
Table 225: Average Cost of Therapy of Vargatef
Table 226: Average Cost of Therapy of Xalkori
Table 227: Average Cost of Therapy of Zykadia
Table 228: Average Cost of Therapy of Keytruda
Table 229: Average Cost of Therapy of Opdivo
Table 230: Average Cost of Therapy of Tecentriq
Table 231: Average Cost of Therapy of Conmana
Table 232: High-Prescribing Physicians Surveyed by Country
1.2 List of Figures
Figure 1: Disease Management Flowchart for nonsquamous NSCLC
Figure 2: Disease Management Flowchart for squamous NSCLC
Figure 3: Disease Management Flowchart for EGFR+ NSCLC
Figure 4: Disease Management Flowchart for ALK+ NSCLC
Figure 5: Tarceva’s Phase III Development in NSCLC
Figure 6: Iressa’s Phase II Development in NSCLC
Figure 7: Gilotrif’s Phase III Development in NSCLC
Figure 8: Tagrisso’s Phase III Development in NSCLC
Figure 9: Portrazza’s Phase II Development in NSCLC
Figure 10: Conmana’s Phase III Development in NSCLC
Figure 11: Xalkori’s Development in NSCLC
Figure 12: Zykadia’s Development in NSCLC
Figure 13: Alecensa’s Development in NSCLC
Figure 14: Opdivo’s Development in NSCLC
Figure 15: Keytruda’s Phase III Development in NSCLC
Figure 16: Tecentriq’s Clincal Development in NSCLC
Figure 17: Avastin’s Phase III Development in NSCLC
Figure 18: Cyramza’s Phase III Development in NSCLC
Figure 19: Vargatef’s Phase II Development in NSCLC
Figure 20: NSCLC - Phase II/III Pipeline, 2016, Part I
Figure 21: NSCLC - Phase II/III Pipeline, 2016, Part II
Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2015-2025
Figure 23: Yervoy’s Clinical Development in NSCLC
Figure 24: Clinical and Commercial Positioning of Yervoy
Figure 25: Estimated Sales of Ipilimumab Biosimilars Versus Branded Yervoy in NSCLC, 2015-2025
Figure 26: Avelumab’s Development in NSCLC
Figure 27: Clinical and Commercial Positioning of Avelumab
Figure 28: Durvalumab’s Clinical Development in NSCLC
Figure 29: Clinical and Commercial Positioning of Durvalumab
Figure 30: Naquotinib’s Clincal Development in NSCLC
Figure 31: Clinical and Commercial Positioning of Naquotinib
Figure 32: Olmutinib’s Clincal Development in NSCLC
Figure 33: Clinical and Commercial Positioning of Olmutinib
Figure 34: Dacomitinib’s Clinical Development in NSCLC
Figure 35: Clinical and Commercial Positioning of Dacomitinib
Figure 36: Ensartinib’s Clinical Development in NSCLC
Figure 37: Clinical and Commercial Positioning of Ensartinib
Figure 38: Brigatinib’s Clinical Development in NSCLC
Figure 39: Clinical and Commercial Positioning of Brigatinib
Figure 40: CimaVax-EGF’s Clinical Development in NSCLC
Figure 41: Clinical and Commercial Positioning of CimaVax-EGF
Figure 42: Tedopi’s Clinical Development in NSCLC
Figure 43: Clinical and Commercial Positioning of Tedopi
Figure 44: Anlotinib’s Clinical Development in NSCLC
Figure 45: Clinical and Commercial Positioning of Anlotinib
Figure 46: Aitan’s Clinical Development in NSCLC
Figure 47: Clinical and Commercial Positioning of Aitan
Figure 48: Fruquintinib’s Clinical Development in NSCLC
Figure 49: Clinical and Commercial Positioning of Fruquintinib
Figure 50: Clinical Development of Avastin Biosimilars in NSCLC
Figure 51: Estimated Sales of Bevacizumab Biosimilars Versus Branded Avastin in NSCLC, 2015-2025
Figure 52: Abemaciclib’s Clinical Development in NSCLC
Figure 53: Clinical and Commercial Positioning of Abemaciclib
Figure 54: Tafinlar + Mekinist’s Clinical Development in NSCLC
Figure 55: Clinical and Commercial Positioning of Tafinlar + Mekinist
Figure 56: Veliparib’s Clinical Development in NSCLC
Figure 57: Clinical and Commercial Positioning of Veliparib
Figure 58: MM-121’s Clinical Development in NSCLC
Figure 59: Clinical and Commercial Positioning of MM-121
Figure 60: IMMU-132’s Clinical Development in NSCLC
Figure 61: Clinical and Commercial Positioning of IMMU-132
Figure 62: Plinabulin’s Clinical Development in NSCLC
Figure 63: Clinical and Commercial Positioning of Plinabulin
Figure 64: Sales for NSCLC in the 5EU by Drug Class, 2015-2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report